(Q47928690)

6 February 2018

title

Prognostic markers in breast cancer: the reliability of HER2/neu status in core needle biopsy of 325 patients with primary breast cancer (English)

1 reference

6 February 2018

author

Michael Gnant

4

1 reference

6 February 2018

author name string

Susanne Taucher

1

1 reference

6 February 2018

Margaretha Rudas

2

1 reference

6 February 2018

Robert M Mader

3

1 reference

6 February 2018

Peter Dubsky

5

1 reference

6 February 2018

Sebastian Roka

6

1 reference

6 February 2018

Thomas Bachleitner

7

1 reference

6 February 2018

Daniela Kandioler

8

1 reference

6 February 2018

Günther Steger

9

1 reference

6 February 2018

Martina Mittlböck

10

1 reference

6 February 2018

Raimund Jakesz

11

1 reference

6 February 2018

publication date

1 January 2004

1 reference

6 February 2018

published in

Vienna Clinical Weekly

1 reference

6 February 2018

volume

116

1 reference

6 February 2018

issue

1-2

1 reference

6 February 2018

page(s)

26-31

1 reference

6 February 2018

https://scigraph.springernature.com/pub.10.1007/bf03040420

exact match

0 references

cites work

Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF03040420

The effects of chemotherapy on morphology, cellular proliferation, apoptosis and oncoprotein expression in primary breast carcinoma

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF03040420

Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer

21 January 2018

1 reference

12 December 2020

Correlation of Histologic Prognostic Factors in Core Biopsies and Therapeutic Excisions of Invasive Breast Carcinoma

1 reference

12 December 2020

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

1 reference

12 December 2020

Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer

1 reference

12 December 2020

Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer

1 reference

12 December 2020

Phase II clinical trial of N-(4-Hydroxyphenyl)retinamide and tamoxifen administration before definitive surgery for breast neoplasia

1 reference

12 December 2020

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

1 reference

12 December 2020

Prognostic and predictive value of HER2/neu oncogene in breast cancer

1 reference

12 December 2020

HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization.

1 reference

12 December 2020

Immunohistochemical determination of HER2 expression in breast cancer from core biopsy specimens: a reliable predictor of HER2 status of the whole tumor

1 reference

12 December 2020

When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer

1 reference

12 December 2020

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

12 December 2020

The use of FISH on breast core needle samples for the presurgical assessment of HER-2 oncogene status

1 reference

12 December 2020

Effect of neoadjuvant chemotherapy on Ki67 labelling index, c-erbB-2 expression and steroid hormone receptor status in human breast tumours

1 reference

12 December 2020

Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message

1 reference

12 December 2020

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

12 December 2020

A comparison of prognostic tumor markers obtained on image-guided breast biopsies and final surgical specimens

1 reference

12 December 2020

Her-2/neu gene amplification compared with HER-2/neu protein overexpression on ultrasound guided core-needle biopsy specimens of breast carcinoma

1 reference

12 December 2020

The role of immunohistochemistry and fluorescence in situ hybridization for HER2/neu in assessing the prognosis of breast cancer

1 reference

12 December 2020

Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy.

1 reference

12 December 2020

Modulation of molecular marker expression by induction chemotherapy in locally advanced breast cancer: correlation with the response to therapy and the expression of MDR1 and LRP

1 reference

12 December 2020

Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system

1 reference

12 December 2020

[Clinical phase II-evaluation of neoadjuvant, cytostatic combination chemotherapy with docetaxel and epidoxorubicin in female breast cancer patients (T1-4, N0-2, M0)]

1 reference

12 December 2020

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

12 December 2020

c-erbB-2 (HER-2/neu) protein and drug resistance in breast cancer patients treated with induction chemotherapy.

1 reference

12 December 2020

Amplification of a novel v-erbB-related gene in a human mammary carcinoma.

1 reference

12 December 2020

Large core biopsy for diagnostic and prognostic evaluation of invasive breast carcinomas

1 reference

12 December 2020

Do prognostic marker studies on core needle biopsy specimens of breast carcinoma accurately reflect the marker status of the tumor?

1 reference

12 December 2020

Current perspectives on HER2 testing: a review of national testing guidelines

1 reference

12 December 2020

Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years

1 reference

12 December 2020

[Is there progress in chemotherapy for breast cancer?]

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03040420

1 reference

6 February 2018

release_vhtb6vtepjh5vfz6dhyxafvw4q

Fatcat ID

0 references

1 reference

6 February 2018